Recent results from a phase IIa clinical trial on DKN-01 in combination with the immune checkpoint inhibitor atezolizumab [an antibody against Programmed cell Death ligand-1 (PD-L1)] in patients with advanced esophagogastric adenocarcinoma (NCT04166721) reported a manageable safety profile without new safety signals due to DKN-01 [109]. This evidence concerns the gene CD274 and gastroesophageal junction adenocarcinoma.